Bullfrog AI Holdings, Inc. is a digital biopharmaceutical company. The Company is focused on advanced artificial intelligence/machine learning (AI/ML)-driven analysis of complex data sets in medicine and healthcare. The Company's platform technology, bfLEAP, is an analytical AI/ML platform that is a... Bullfrog AI Holdings, Inc. is a digital biopharmaceutical company. The Company is focused on advanced artificial intelligence/machine learning (AI/ML)-driven analysis of complex data sets in medicine and healthcare. The Company's platform technology, bfLEAP, is an analytical AI/ML platform that is a potentially disruptive tool for the analysis of pre-clinical and/or clinical data sets, such as the robust pre-clinical and clinical trial data sets being generated in translational R&D and clinical trial settings. The platform can capture the genetic and physical characteristics of patients in an unbiased manner and contextualize them against other disparate data sources from patients. The Company's therapeutic pipeline includes siRNA and Mebendazole. Its siRNA targets Beta2-spectrin in the treatment of human diseases such as hepatocellular carcinoma (HCC), obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis. Mebendazole is focused on targeting Glioblastoma. 더 보기
GAITHERSBURG, Md., Jan. 10, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using...
GAITHERSBURG, Md., Dec. 27, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using...
GAITHERSBURG, Md., Dec. 17, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using...
GAITHERSBURG, Md., Oct. 22, 2024 (GLOBE NEWSWIRE) -- BullFrog AI, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial...
WallachBeth Capital Announces Closing of Bullfrog AI Registered Direct Offering and Concurrent Private Placement for Aggregate Gross Proceeds of $3.13 Million PR Newswire JERSEY CITY, N.J., Oct...
GAITHERSBURG, Md., Oct. 21, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) ("Bullfrog AI" or the "Company"), a technology-enabled drug development company using...
WallachBeth Capital Announce Pricing of Bullfrog AI's Registered Direct Offering and Concurrent Private Placement for Aggregate Gross Proceeds of $3.13 Million PR Newswire JERSEY CITY, N.J., Oct...
GAITHERSBURG, Md., Oct. 18, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) ("Bullfrog AI" or the "Company"), a technology-enabled drug development company using...
GAITHERSBURG, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- BullFrog AI, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial...
The study, led by Dr. Lopa Mishra and published in Cell Reports, provides new mechanistic evidence for role of BF-114 target β2-spectrin in obesity, MASLD, MASH, and HCCThe findings suggest that...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.2001 | -7.69615384615 | 2.6 | 2.75 | 2.1501 | 442600 | 2.43780479 | CS |
4 | 0.3099 | 14.8277511962 | 2.09 | 2.95 | 2.0101 | 453493 | 2.4629184 | CS |
12 | -0.1501 | -5.8862745098 | 2.55 | 2.95 | 1.95 | 275284 | 2.38048333 | CS |
26 | -0.5601 | -18.9222972973 | 2.96 | 3.2 | 1.95 | 166515 | 2.45667893 | CS |
52 | -3.2001 | -57.1446428571 | 5.6 | 5.8938 | 1.4304 | 205430 | 3.09247547 | CS |
156 | -2.9001 | -54.7188679245 | 5.3 | 9.5 | 1.4304 | 915896 | 4.67714452 | CS |
260 | -2.9001 | -54.7188679245 | 5.3 | 9.5 | 1.4304 | 915896 | 4.67714452 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관